Emerging treatments and therapeutic targets for tuberous sclerosis complex in children
- 2 September 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Orphan Drugs
- Vol. 7 (9) , 373-381
Abstract
Introduction: Tuberous sclerosis complex (TSC) is a genetic disease affecting 1:6000 newborns. It is a multisystem disease caused by overactivation of mechanistic target of rapamycin (mTOR) pathway and associated with the development of many benign tumors in different organs (e.g. brain, skin, kidney, lungs, heart) and comorbidities including epilepsy, cognitive impairment, neuropsychiatric disorders. In recent years, some new therapeutic agents and strategies have emerged for TSC. Areas covered: In the article, authors discuss the results of recent studies particularly on epilepsy management including preventive antiepileptic treatment in TSC infants, current studies on cannabidiol, and an increasing role of mTOR inhibitors (sirolimus, everolimus) in the treatment of many TSC manifestations. Expert opinion: Recent years and studies resulted in significant progress in the therapy of TSC. Prevention of epilepsy in TSC children with subsequent improvement of cognitive outcome is currently possible. The question about the duration of preventive treatment in children who did not experience seizures will still be open. Considering the increasing role of mTOR inhibitors, the possibility of not only therapeutic but also preventive role of these drugs for TSC manifestations may be a question for future research.Keywords
This publication has 75 references indexed in Scilit:
- Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget EffectPLOS ONE, 2013
- Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complexNature Communications, 2012
- Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels DecreasePLOS ONE, 2011
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathwayEpilepsia, 2011
- The natural history of epilepsy in tuberous sclerosis complexEpilepsia, 2010
- Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis ComplexJournal of Child Neurology, 2008
- Renal Cell Carcinoma in Young and Old Patients—Is There a Difference?Journal of Urology, 2008
- Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosisNature Medicine, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008